Shomron Ben-Horin
@ShomronH
Followers
2K
Following
977
Media
175
Statuses
1K
M.D.Professor & Chief#Gastroenterology Dept, Sheba Medical Center. Focus# Crohns&Colitis. Director#IBDPassport. Worked Israel, USA, China. Ìnnovate and help!
Joined June 2021
Now in press at @AGA_CGH promising results PCB trial of curcumin-QingDai (CurQD) botanical combo. Shown to be a unique AhR agonist which was effective for active UC pts, half of whom IMM/biologics exprienced. my COI of note. @AmerGastroAssn #nutrition
https://t.co/vRRjzO6x2n
13
40
140
A polyp underneath the IC valve which I could only see (and lift-resect-STC) when retroflexing in cecum with a pediatric scope. Right colon retroflexion is not guidelines and carries potential risk, but such cases make me keep doing it (though without insisting too much....)
1
1
16
Very nice pathway expression work supporting that 'anastomositis' is in fact inherently Crohn. Would be nice to look into CRC/diverticulitis anastomoses (which seldom inflame) for comparison with non inflamed CD ones
Our work on post-operative #crohns: Biopsies from the ileum, anastomosis and colon: Inflammation at the anastomosis is the same as inflammation in the colon/ileum, it is not hypoxia! should we treat? @JeanFredericCo1 @Bealoquebea @IBDimmunology
https://t.co/LIP9E7rnIi
0
0
2
New publication! Our study shows that CADe introduction did not improve surveillance colonoscopy performance in #IBD patients. Highlights the need for IBD-specific CADe tools & attention to physician-AI dynamics. https://t.co/PSi3KWDJ7h
@IBDJournals @UriKopylov @ShomronH
academic.oup.com
AbstractObjectives. The real-world efficacy of computer-aided detection (CADe) in improving surveillance colonoscopy performance for patients with inflamma
0
6
10
Psychologist-led group therapy for IBD often very helpful & supportive. Kudo to the fantastic #Dr. Ellen Joseph from @GIPsychUSA for leading this very nice 🇺🇲 initiative with @CrohnsColitisFn We need this all over the 🌍
0
3
7
Terminated development: Combo aTNF+anti FcRn nipocalimab (basically a non-selective IgG reducing strategy) no better than aTNF alone in RA. Further supporting RA (and IBD?) related Ab are not pathogenic but an epiphenomenon...? https://t.co/9zkJdyeKbS
finance.yahoo.com
Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-...
3
3
13
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis - Clinical Gastroenterology and Hepatology
cghjournal.org
Tofacitinib and upadacitinib are Janus kinase (JAK) inhibitors that are increasingly used for the treatment of acute severe ulcerative colitis (ASUC). However, comparative analyses of safety and...
1
21
35
Unique trial & encorouging results of Vedo-Tofa (VETO) combination after failure of either Vedo or Tofa. 14/24 pts had CS free remission W24. What remains unanswered is whether these results would be superior to simply switching to the other agent.
With increasing refractory IBD .. we found VETO a feasible option.. with generics and biosimilars in the near pipeline hopefully the cost concerns will be lessened .
1
2
10
With caveat of non controlled study & small size (and my COI), still nice to have first RWE signal on efficacy of #CurQD in Crohn, not only UC
1st real-world study of CurQD® in CD now out in Frontiers in Gastro 🧪 Pts w/ active CD (incl. prior biologics) saw clinical + biomarker gains by Wk 12 — most stayed better long-term. https://t.co/LbKxwP5w7b
#IBD #Crohns #CurQD #RWE #GI #Evinature
0
5
16
Important prospective large 🇪🇦 cohort study showing baseline healthy MD diet & lifestyle reduces risk of IBD flare during follow up. Will it be the same in 🇺🇲 ? or perhaps even more accentuated d/t worse bacground diet ??
And also matters after diagnosis, at least good diet has an effect in clinical course in some populations https://t.co/MTVL17ixkR
0
5
17
Very interesting study of Yao (NOD2 associated) syndrome, expanding the scope of IBD adjacent disorders (like CMUSE, but very different). Mostly GI motility manifestations but periodic fevers and joints are more like FMF/TRAP.
⭐️I am thrilled to share our latest publication, which describes the gastrointestinal manifestations of Yao Syndrome (NOD2-associated autoinflammatory disease)! https://t.co/62IeUNbz6i
#MedTwitter #GITwitter #rheumatology #rheumtwitter #YaoSyndrome #YAOS
0
4
13
A bombshell metaanalysis just landed in @AGA_CGH : Advanced therpies work better in colonic #Crohn vs. Ileal dis 😱 aTNFs/aIL23-aIL12/23 were all more effective in the colon, aIntegrin same efficacy in both(?), and JAKi were ONLY EFFECTIVE IN COLON.... https://t.co/fuuo1GExEv
cghjournal.org
We compared the efficacy of different advanced therapies by disease location in patients with Crohn’s disease (CD) through a systematic review and meta-analysis.
14
48
126
Elegant study on isolated anastomotic ulceration ("pure"i2a) shows they also predict higher recurrence risk (and linked with dysbiosis). Bears to reason, as they are rarely seen in non-IBD anastomoses
1/ Our new study at IBD Journal linking Isolated Anastomotic Ulcer (IAU) to long-term recurrence post-operatively and microbiome shifts. @MichielBak @poliverasendra @TurpinWilliams @HaimLeiboIBD @guthealthmd @SinaiHealth
@AnthonydeBuck @mantaj_brar
https://t.co/WBfA6aLs7c
1
2
18
If you read this month's Editor's Essential Reading, "Capsule Endoscopy–Guided Proactive Treat-to-Target Versus Continued Standard Care in Patients With Quiescent Crohn’s Disease," check out the corresponding editorial by @IBD_FloMD et al. ➡️
2
5
15
Very cool pictorial. To add: Both Risa and Miri have Fc LALA mutation to reduce effector ADCC/CDC potential. In contrast, Gus is wild type Ab (unmutated, hence binds CD64=FcRI), but still given/4w or/8w. Whether wild type will yield ⬆️AE or better efficacy remains to be seen.
🎯 Extending the Half-Life of mAbs: Why It Matters in IBD In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems. 🧬 Enter Fc engineering: By tweaking the Fc region of
2
6
27
We're scratching the surface in exploiting #IUS potential as a dynamic test in GI. Intetedting observation from @elrets
A physiological/philosophical conundrum On IUS Many patients with IBS have fluid filled loops of small bowel and sometimes a somewhat prominent and hyperechoic submucosa What causes the ⬆️ echogenicity? @CathyLuMD @KrugCleveland @DrMikeDolinger @BowelUltrasound @novakkerri
0
2
5
IUS also for monitoring acute severe UC. Intriguingly, loss of stratification (IUS transmural feature) correlated best with CRP (the transmural biomarker ).
Our study on IUS in ASUC out in @ACG_CTG! @IBDCedarsSinai @iUSCAN @BowelUltrasound 📍IUS bridges discrepancy b/w sx's &🩸markers 📍IBUS-SAS & Milan-UC > IUS-UC for detecting severe endo🔥 📍⬇️BWS correlated more w/ CRP and UCEIS than BWT https://t.co/aoGNDDbHwR
0
2
13
‼️Anyone interested in organ fibrosis please join us for the Keystone Fibrosis Symposium 2026 ‘Cross Organ Pathology and Pathways to Clinical Development’ ‼️Introduction video can be found here https://t.co/l06X0Oo1Ku. Registration 👉🏻 https://t.co/5mc1ANKkHM
@Suzanne_Devkota
4
24
56
💯 Thank u for sharing ! Really moving to hear. Wish u best of health
@ShomronH @natekrugliak @guthealthmd @UofT I’m this patient and I’m still using curqd and I’m still in remission!!
0
1
6
Nice case report from @natekrugliak and @guthealthmd in Toronto, on use of #CurQD for a #Crohn patient who flared after having to stop IFX due to dilated cardiomyopathy @UofT My COI of note https://t.co/bWMcfSNMA1
2
13
35
As noted in this paper, we dont give prep to SB capsule. Unwarranted, and turns a pt-friendly procedure into much less so
The Visibility and Performance of Small Bowel Video Capsule Endoscopy With and Without Pre‐Procedural Purge Preparation in the Same Patients - Margalit Yehuda - 2025 @SHEBA_ @JGHofficial - Wiley Online Library
1
4
5